A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

drug protocol number

221530

drug sponsor

GlaxoSmithKline / Balsam

drug study

Dostarlimab (GSK4057190)

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh),King Saud University Medical City (Riyadh), King Abdullah International Medical Research Center (Riyadh)

drug status

Ongoing

drug phase